Pacira BioSciences has sent a letter to stockholders ahead of its 2026 Annual Meeting urging them to vote for its three highly qualified board nominees who have extensive experience in healthcare and biopharmaceuticals. The company criticizes DOMA Perpetual Capital Management's nominees as underqualified and lacking relevant industry expertise, warning that their election could harm shareholder value. Pacira highlights its successful 5x30 strategy aimed at sustainable growth and accuses DOMA of lacking a clear plan and understanding of the biotech industry. Stockholders are encouraged to use the BLUE proxy card to support Pacira's nominees and reject DOMA's candidates to protect long-term company value.
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Viasat and BMW Group have successfully demonstrated the first integrated automotive satellite voice call, allowing drivers to make calls directly through the car's infotainment system even in areas without cellular coverage. This advancement, utilizi...
Iran has warned it will retaliate fiercely if the US targets its infrastructure, following President Trump's threat to strike Iranian power plants and bridges next week if negotiations fail. The US recently conducted airstrikes against Iranian milita...
Solana (SOL) maintains its price in the mid-$70 range, supported by several key developments. These include Circle's recent issuance of $500 million in USDC on the Solana network, increasing liquidity and transactional demand. Additionally, instituti...
